National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pharmacoeconomic evaluation of Ipilimumab (Yervoy®) for the treatment of advanced (unresectable or metastatic) melanoma in adult patients who have received prior therapy.

Rapid Review

Commenced Completed Outcome
31/05/2011 09/06/2011 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
29/07/2011 02/09/2011 Reimbursement not recommended at the submitted price.

We cannot recommend reimbursement of Ipilimumab at the submitted price.

 Ipilimumab (Yervoy) summary

September 2013

The HSE has approved reimbursement following confidential price negotiations.